Senseonics (NYSE:SENS) shares dipped after hours today on first-quarter results that beat revenue projections on Wall Street.
Shares of SENS fell 5% to 70¢ apiece in post-market trading today.
The Germantown, Maryland-based long-term implantable continuous glucose monitor maker reported losses of $14.3 million. That equals 2¢ per share on sales of $6.26 million for the three months ended March 31, 2025.
Senseonics recorded a more than $4 million bottom-line gain on a sales increase of 24%.
Losses per share landed level with expectations on Wall Street. Sales topped forecasts as experts estimated $5.56 million in revenue.
Recent highlights include the integration of the company’s 365-day CGM with the Sequel twiist automated insulin delivery system. Senseonics also says it submitted its Eversense 365 for CE mark and expects a European launch in the second half of this year.
“We continue to execute on our strategy to make Eversense easier for people with diabetes to access and more flexible to use, always driving to continually improve the world’s only long-duration CGM platform,” said Tim Goodnow, president and CEO of Senseonics. “Securing positive CMS reimbursement of our one-year CGM, effective from January 1, was a major milestone for access, and our collaboration with Sequel is the important next step towards providing a convenient solution that integrates state of the art continuous glucose monitoring and insulin delivery technologies. Together with progress towards launching Eversense 365 in Europe, collaborations such as Sweet Spot, and development on Gemini and Freedom, we are delivering advances to improve the lives of the people we serve.”
Senseonics reaffirmed its guidance for between $34 million and $38 million as it continues to roll out Eversense 365 to U.S. patients.
The analysts’ take on Senseonics
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang maintained their “Neutral” rating for Senseonics after the quarterly results.
The analysts note that Senseonics posted its revenue beat thanks to outperformance in the U.S. and outside the U.S. They said the company reported utilization through the office consignment channel as well.
Senseonics’ guidance includes the potential approval and launch of Eversense 365 in Europe and the analysts say that should offset a shortfall following a pause in the company’s remote patient monitoring collaboration with Mercy Health system after executive restructuring.
Additionally, analysts note potential tariff headwinds as Senseonics uses contract manufacturers in Europe and sources components globally, including “a very small percentage” in China. Management expects to mitigate any potential headwinds by leveraging exemptions and through operational changes to the supply chain.
“We are pleased to see increasing sales momentum from the 365-day Eversense system in the U.S. and believe we could see similar trends in Europe once approved,” the analysts said. “We are also upbeat on the opportunity to integrate Eversense 365 with Sequel Med Tech’s twiist automated insulin delivery (AID) system. [Senseonics] expects the integrated system with the Loop algorithm to be available starting in Q3. For now, we remain on the sidelines as we await a clear signal of consistent commercial traction.”
